HC Wainwright & Co. Reiterates Buy on Citius Pharma, Maintains $4 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Vernon Bernardino has reiterated a 'Buy' rating on Citius Pharma (NASDAQ:CTXR) and maintained a $4 price target.
August 10, 2023 | 4:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Citius Pharma's stock rating has been reiterated as 'Buy' by HC Wainwright & Co. with a maintained price target of $4.
The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for investors. The maintained price target of $4 indicates the firm's confidence in the stock's potential to reach this price, which could drive investor interest and potentially increase the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100